LFCR icon

Lifecore Biomedical

6.66 USD
-0.77
10.36%
At close Jan 2, 4:00 PM EST
After hours
7.01
+0.35
5.26%
1 day
-10.36%
5 days
-13.17%
1 month
-12.71%
3 months
34.00%
6 months
41.10%
Year to date
4.39%
1 year
4.39%
5 years
-40.38%
10 years
-52.09%
 

About: Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.

Employees: 524

0
Funds holding %
of 6,812 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

290% more call options, than puts

Call options by funds: $425K | Put options by funds: $109K

146% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 13

58% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 12

25% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 5 (+1) [Q3]

9% more funds holding

Funds holding: 74 [Q2] → 81 (+7) [Q3]

1.34% less ownership

Funds ownership: 69.1% [Q2] → 67.76% (-1.34%) [Q3]

5% less capital invested

Capital invested by funds: $123M [Q2] → $117M (-$6.24M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$10
50%
upside
Avg. target
$10
50%
upside
High target
$10
50%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Craig-Hallum
Matthew Hewitt
100% 1-year accuracy
2 / 2 met price target
50%upside
$10
Buy
Maintained
22 Nov 2024

Financial journalist opinion

Based on 13 articles about LFCR published over the past 30 days

Neutral
GlobeNewsWire
4 hours ago
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update
-- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Customers --
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update
Neutral
Accesswire
10 hours ago
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Neutral
Accesswire
10 hours ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation
Neutral
Accesswire
3 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation
Neutral
Accesswire
4 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect
Neutral
GlobeNewsWire
2 weeks ago
Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the second quarter of fiscal year 2025 on Thursday, January 2, 2025, after market close.
Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
Neutral
GlobeNewsWire
2 weeks ago
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
Charts implemented using Lightweight Charts™